



RECEIVED  
JUL 07 2003  
TECH CENTER 16012900  
VPI/001083  
/615

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : L. Helms  
Group Art Unit : 1615  
Applicants : Bhami Shenoy et al.  
Application No. : 10/034,950 Confirmation No.: 9344  
Filed : December 26, 2001  
For : CRYSTALS OF WHOLE ANTIBODIES AND  
FRAGMENTS THEREOF AND METHODS FOR  
MAKING AND USING THEM

New York, New York  
June 27, 2003

Hon. Commissioner  
for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR  
INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith is an Information Disclosure  
Statement in the above-identified application. This  
Statement is submitted:

- ☐ within three months of the application filing date;
- ☒ more than three months from the application filing date but before the mailing date of the first Office Action on the merits.

In accordance with 37 C.F.R. § 1.97, submission of  
this Statement requires no fee. However, if for any reason  
a fee is due, the Director is hereby authorized to charge

payment of any fees required in connection with this  
Information Disclosure Statement to Deposit Account  
No. 06-1075. A duplicate copy of this letter is transmitted  
herewith.

Respectfully submitted,




Margaret A. Pierri (Reg. No. 30,709)  
Attorney for Applicants  
Andrew K. Holmes (Reg. No. 51,813)  
Agent for Applicants  
c/o FISH & NEAVE  
1251 Avenue of the Americas  
New York, New York 10020  
Tel.: (212) 596-9000

I hereby certify that this  
Correspondence is being  
deposited with the U.S.  
Postal Service as First  
Class Mail in an envelope  
Addressed to:  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450 on

June 27, 2003

Lillian Garcia

  
Signature of Person Signing



VPI/00008

JUL 07 2003  
TECH CENTER 1600/2900

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : L. Helms  
Group Art Unit : 1615  
Applicants : Bhami Shenoy et al.  
Application No. : 10/034,950 Confirmation No.: 9344  
Filed : December 26, 2001  
For : CRYSTALS OF WHOLE ANTIBODIES AND  
FRAGMENTS THEREOF AND METHODS FOR MAKING  
AND USING THEM

New York, New York  
June 27, 2003

Hon. Commissioner  
for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants,  
through their representatives, hereby make of record the  
documents listed in the accompanying Form PTO-1449, enclosed  
herewith in duplicate. Copies of these documents are enclosed.

UNITED STATES PATENTS

Johal, U.S. Patent 4,334,024 (6/8/82);  
Bosch et al., U.S. Patent 5,510,118 (4/23/96);  
Eckenhoff et al., U.S. Patent 5,904,935 (5/18/99);  
Navia et al., U.S. Patent 6,011,001 (1/4/00);  
Khalaf, U.S. Patent 6,042,824 (3/28/00); and  
Margolin et al., U.S. Patent 6,140,475 (10/31/00).

### FOREIGN APPLICATIONS

PCT Publication WO 91/09943, published July 11, 1991  
PCT Publication WO 96/40049, published December 19, 1996  
PCT Publication WO 99/55310, published November 4, 1999  
PCT Publication WO 00/52150, published September 8, 2000

### OTHER DOCUMENTS

Baselga et al., "Recombinant Humanized Anti-HER2 Antibody (Herceptin) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts," Cancer Res., Volume 58, pp. 2825-31 (1998).

Bertolini et al., Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma," Neoplasia, Volume 96, pp. 282-87 (2000).

Blanco et al., "Protein encapsulation and release from poly(lactide-co-glycolide) microspheres: effect of the protein and polymer properties and of the co-encapsulation of surfactants," Eur. J. Pharm. Biopharm. Volume 45, pp. 285-94 (1998).

Braden et al., "X-ray crystal structure of an anti-Buckminsterfullerene antibody Fab fragment: Biomolecular recognition of C<sub>60</sub>," Proc. Natl. Acad. Sci. USA, Volume 97, pp. 12193-97 (2000).

Brange et al., "Chemical Stability of Insulin. 1. Hydrolytic Degradation During Storage of Pharmaceutical Preparations," Pharm. Res., Volume 9, pp. 715-26 (1992).

Covaceuszach et al., "Purification, crystallization and preliminary X-ray analysis of the Fab fragment from MNAC13, a novel antagonistic anti-tyrosine kinase A receptor monoclonal antibody," Acta. Crystallogr. D. Biol. Crystallogr., Volume 57, pp. 1307-09 (2001).

Dong et al., "Secondary Structure of the Pentraxin Female Protein in Water Determined by Infrared Spectroscopy: Effects of Calcium and Phosphorylcholine," Biochemistry, Volume 31, pp. 9364-70 (1992).

Dong et al., "Infrared Spectroscopic Studies of Lyophilization- and Temperature-Induced Protein Aggregation," J. Pharm. Sci., Volume 84, pp. 415-24 (1995).

Harris et al., "Comparison of the conformations of two intact monoclonal antibodies with hinges," Immunol. Rev., Volume 163, pp. 35-43 (1998).

Harris et al., "Crystallographic Structure of an Intact IgG1 Monoclonal Antibody," J. Mol. Biol., Volume 275, pp. 861-872 (1998).

Ito, et al., "Crystallization and preliminary X-ray crystallographic studies on a Fab fragment of the mouse anti-human Fas monoclonal antibody HFE7A," Acta. Crystallogr. D. Biol. Crystallogr., Volume D57, pp. 1700-1702 (2001).

Kim et al., "Gene therapy for established murine collagen-induced arthritis by local and systemic adenovirus-mediated delivery of interleukin-4," Arthritis Res., Volume 2, pp. 293-302 (2000).

Küttner et al., "A phage library-derived single-chain Fv fragment in complex with turkey egg-white lysozyme: characterization, crystallization and preliminary X-ray analysis," Molecular Immunology, Volume 35, pp. 189-194 (1998).

Malfait et al., "Chronic Relapsing Homologous Collagen-Induced Arthritis in DBA/1 Mice as a Model for Testing Disease-Modifying and Remission-Inducing Therapies," Arthritis Rheum., Volume 44, pp. 1215-24 (2001).

McPherson, "Preliminary Analysis: Mounting and aligning procedures," in Preparation and Analysis of Protein

Crystals, pp. 214-27 (John Wiley & Sons Publishing) (1989).

Mylvaganam et al., "Structural Basis for the Binding of an Anti-cytochrome *c* Antibody to its Antigen: Crystal Structures of FabE8-Cytochrome *c* Complex to 1.8 Å Resolution and FabE8 to 2.26 Å Resolution," J. Mol. Biol., Volume 281, pp. 301-22 (1998).

Pekarek et al., "Double-walled polymer microspheres for controlled drug release," Nature, Volume 367, pp. 258-60 (1994).

Pichla et al. "The Crystal Structure of a Fab Fragment to the Melanoma-Associated GD2 Ganglioside," J. Struct. Biol., Volume 119, pp. 6-16 (1997).

Pietras et al., "Monoclonal Antibody to HER-2/*neu* Receptor Modulates Repair of Radiation-induced DNA Damage and Enhances Radiosensitivity of Human Breast Cancer Cells Overexpressing This Oncogene," Cancer Research, Volume 59, pp. 1347-1355 (1999).

Pikal et al., "Quantitative Crystallinity Determinations for  $\beta$ -Lactam Antibiotics by Solution Calorimetry: Correlations with Stability," J. Pharm. Sci., Volume 67, pp. 767-73 (1978).

Pikal et al., "The Stability of Insulin in Crystalline and Amorphous Solids: Observation of Greater Stability for the Amorphous Form," Pharm. Res., Volume 14, pp. 1379-87 (1997).

Rodgers, "Practical Cryocrystallography," Methods in Enzymology, Volume 276, pp. 183-203 (1997).

Saul et al., "Structure of the Fab fragment from F124, a monoclonal antibody specific for hepatitis B surface antigen," Acta. Crystallogr. D. Biol. Crystallogr., Volume D56, pp. 945-951 (2000).

Shenoy et al., "Stability of Crystalline Proteins,  
Biotechnol. Bioeng., Volume 73, pp. 358-69 (2001).

Sohi et al., "Crystallization and Preliminary X-ray  
Analysis of the Fab Fragment of a Human Monoclonal IgM  
Rheumatoid Factor (2A2)," J. Mol. Biol., Volume 242,  
pp. 706-08 (1994).

Sullivan et al., "Sustained release of progesterone and  
estradiol from the SABER™ delivery system: In vitro and  
in vivo release rates," Proceed. Int'l. Symp. Control.  
Rel. Bioact. Mater., Volume 25, pp. 653-54 (1998).

Yoshino, "Treatment with an Anti-IL-4 Monoclonal  
Antibody Blocks Suppression of Collagen-Induced  
Arthritis in Mice by Oral Administration of Type II  
Collagen," J. Immunol., Volume 160, pp. 3067-3071  
(1998).

It is respectfully requested that the enclosed  
documents be (1) fully considered by the Examiner during the  
examination of this application; and (2) printed on any patent  
which may issue on this application. Applicants request that a  
copy of Form PTO-1449, as considered and initialed by the  
Examiner, be returned with the next communication.

Respectfully submitted,




Margaret A. Pierri (Reg. No. 30,709)  
Attorney for Applicants  
Andrew K. Holmes (Reg. No. 51,813)  
Agent for Applicants  
c/o FISH & NEAVE  
1251 Avenue of the Americas  
New York, New York 10020  
Tel.: (212) 596-9000

I hereby certify that this  
Correspondence is being  
deposited with the U.S.  
Postal Service as First  
Class Mail in an envelope  
Addressed to:  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450 on

June 27, 2003

Lillian Garcia

  
Signature of Person Signing

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
VPI/00-08APPLICATION  
NO. 10/034,950INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTAPPLICANT  
Shenoy et al.CONF. NO.  
9344FILING DATE  
December 26, 2001GROUP  
1615

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,334,024	6/8/82	Johal	435	232	
	5,510,118	4/23/96	Bosch et al.	424	489	
	5,904,935	5/18/99	Eckenhoff et al.	424	489	
	6,011,001	1/4/00	Navia et al.	514	2	
	6,042,824	3/28/00	Khalaf	424	94.6	
	6,140,475	10/31/00	Margolin et al.	530	402	

RECEIVED

JUL 07 2003

TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 91/09943	7/11/91	PCT	C12N	9/98		
	WO 96/40049	12/19/96	PCT	A61K	9/00		
	WO 99/55310	11/4/99	PCT	A61K	9/86		
	WO 00/52150	9/8/2000	PCT	C12N	7/00		

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


EXAMINER INITIAL	
	Baselga et al., "Recombinant Humanized Anti-HER2 Antibody (Herceptin) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts," <u>Cancer Res</u> , Volume 58, pp. 2825-31 (1998).
	Bertolini et al., Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma," <u>Neoplasia</u> , Volume 96, pp. 282-87 (2000).
	Blanco et al., "Protein encapsulation and release from poly(lactide-co-glycolide) microspheres: effect of the protein and polymer properties and of the co-encapsulation of surfactants," <u>Eur. J. Pharm. Biopharm.</u> Volume 45, pp. 285-94 (1998).
	Braden et al., "X-ray crystal structure of an anti-Buckminsterfullerene antibody Fab fragment: Biomolecular recognition of C <sub>60</sub> ," <u>Proc. Natl. Acad. Sci. USA</u> , Volume 97, pp. 12193-97 (2000).
	Brange et al., "Chemical Stability of Insulin. 1. Hydrolytic Degradation During Storage of Pharmaceutical Preparations," <u>Pharm. Res.</u> , Volume 9, pp. 715-26 (1992).
	Covaceuszach et al., "Purification, crystallization and preliminary X-ray analysis of the Fab fragment from MNAC13, a novel antagonistic anti-tyrosine kinase A receptor monoclonal antibody," <u>Acta. Crystallogr. D. Biol. Crystallogr.</u> , Volume 57, pp. 1307-09 (2001).
	Dong et al., "Secondary Structure of the Pentraxin Female Protein in Water Determined by Infrared Spectroscopy: Effects of Calcium and Phosphorylcholine," <u>Biochemistry</u> , Volume 31, pp. 9364-70 (1992).
	Dong et al., "Infrared Spectroscopic Studies of Lyophilization- and Temperature-Induced Protein Aggregation," <u>J. Pharm. Sci.</u> , Volume 84, pp. 415-24 (1995).



JUL 07 2003

TECH CENTER 1600/2000

Sheet 2 of 3


 U.S. DEPARTMENT OF COMMERCE  
 PATENT AND TRADEMARK OFFICE

 INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT

 ATTY. DOCKET NO.  
 VPI/00-08

 APPLICANT  
 Shenoy et al.

 FILING DATE  
 December 26, 2001

 APPLICATION  
 NO. 10/034,950


 CONF. NO.  
 9344

 GROUP  
 1615

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Harris et al., "Comparison of the conformations of two intact monoclonal antibodies with hinges," <i>Immunol. Rev.</i> , Volume 163, pp. 35-43 (1998).
	Harris et al., "Crystallographic Structure of an Intact IgG1 Monoclonal Antibody," <i>J. Mol. Biol.</i> , Volume 275, pp. 861-872 (1998).
	Ito, et al., "Crystallization and preliminary X-ray crystallographic studies on a Fab fragment of the mouse anti-human Fas monoclonal antibody HFE7A," <i>Acta. Crystallogr. D. Biol. Crystallogr.</i> , Volume D57, pp. 1700-1702 (2001).
	Kim et al., "Gene therapy for established murine collagen-induced arthritis by local and systemic adenovirus-mediated delivery of interleukin-4," <i>Arthritis Res.</i> , Volume 2, pp. 293-302 (2000).
	Küttner et al., "A phage library-derived single-chain Fv fragment in complex with turkey egg-white lysozyme: characterization, crystallization and preliminary X-ray analysis," <i>Molecular Immunology</i> , Volume 35, pp. 189-194 (1998).
	Malfait et al., "Chronic Relapsing Homologous Collagen-Induced Arthritis in DBA/1 Mice as a Model for Testing Disease-Modifying and Remission-Inducing Therapies," <i>Arthritis Rheum.</i> , Volume 44, pp. 1215-24 (2001).
	McPherson, "Preliminary Analysis: Mounting and aligning procedures," in <i>Preparation and Analysis of Protein Crystals</i> , pp. 214-27 (John Wiley & Sons Publishing) (1989).
	Mylvaganam et al., "Structural Basis for the Binding of an Anti-cytochrome c Antibody to its Antigen: Crystal Structures of FabE8-Cytochrome c Complex to 1.8 Å Resolution and FabE8 to 2.26 Å Resolution," <i>J. Mol. Biol.</i> , Volume 281, pp. 301-22(1998).
	Pekarek et al., "Double-walled polymer microspheres for controlled drug release," <i>Nature</i> , Volume 367, pp. 258-60 (1994).
	Pichla et al. "The Crystal Structure of a Fab Fragment to the Melanoma-Associated GD2 Ganglioside," <i>J. Struct. Biol.</i> , Volume 119, pp. 6-16 (1997).
	Pietras et al., "Monoclonal Antibody to HER-2/ <i>neu</i> Receptor Modulates Repair of Radiation-induced DNA Damage and Enhances Radiosensitivity of Human Breast Cancer Cells Overexpressing This Oncogene," <i>Cancer Research</i> , Volume 59, pp. 1347-1355 (1999).
	Pikal et al., "Quantitative Crystallinity Determinations for $\beta$ -Lactam Antibiotics by Solution Calorimetry: Correlations with Stability," <i>J. Pharm. Sci.</i> , Volume 67, pp. 767-73 (1978).
	Pikal et al., "The Stability of Insulin in Crystalline and Amorphous Solids: Observation of Greater Stability for the Amorphous Form," <i>Pharm. Res.</i> , Volume 14, pp. 1379-87 (1997).
	Rodgers, "Practical Cryocrystallography," <i>Methods in Enzymology</i> , Volume 276, pp. 183-203 (1997).
	Saul et al., "Structure of the Fab fragment from F124, a monoclonal antibody specific for hepatitis B surface antigen," <i>Acta. Crystallogr. D. Biol. Crystallogr.</i> , Volume D56, pp. 945-951 (2000).
	Shenoy et al., "Stability of Crystalline Proteins," <i>Biotechnol. Bioeng.</i> , Volume 73, pp. 358-69 (2001).
	Sohi et al., "Crystallization and Preliminary X-ray Analysis of the Fab Fragment of a Human Monoclonal IgM Rheumatoid Factor (2A2)," <i>J. Mol. Biol.</i> , Volume 242, pp. 706-08 (1994).
	Sullivan et al., "Sustained release of progesterone and estradiol from the SABER™ delivery system: In vitro and in vivo release rates," <i>Proceed. Int'l. Symp. Control. Rel. Bioact. Mater.</i> , Volume 25, pp. 653-54 (1998).

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
VPI/00-08APPLICATION  
NO. 10/034,950INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTAPPLICANT  
Shenoy et al.CONF. NO.  
9344FILING DATE  
December 26, 2001GROUP  
1615

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Yoshino, "Treatment with an Anti-IL-4 Monoclonal Antibody Blocks Suppression of Collagen-Induced Arthritis in Mice by Oral Administration of Type II Collagen," <u>J. Immunol.</u> , Volume 160, pp. 3067-3071 (1998).